ROCKWELL MEDICAL, INC. Debt Securities, Available-for-sale, Amortized Cost
ROCKWELL MEDICAL, INC. (RMTI) had Debt Securities, Available-for-sale, Amortized Cost of $9.14 million as of 2021-12-31, per its 10-K filed 2022-04-08.
Discontinued › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-04-08
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $9.14M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $9.99M.
- 2019-12-31: Debt Securities, Available-for-sale, Amortized Cost $14.24M; Debt Securities, Available-for-sale, Amortized Cost as first filed $14.24M.
- 2018-12-31: Debt Securities, Available-for-sale, Amortized Cost $10.80M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2021-12-31 | $9.14M 10-K · filed 2022-04-08 | |
| 2020-12-31 | $9.99M 10-K · filed 2022-04-08 | |
| 2019-12-31 | $14.24M 10-K · filed 2021-03-31 | $14.24M 10-K · filed 2020-03-17 |
| 2018-12-31 | $10.80M 10-K · filed 2020-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |